TY - JOUR
T1 - Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005
T2 - Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age
AU - McCarthy, Philip L.
AU - Hahn, Theresa
AU - Hassebroek, Anna
AU - Bredeson, Christopher
AU - Gajewski, James
AU - Hale, Gregory
AU - Isola, Luis
AU - Lazarus, Hillard M.
AU - Lee, Stephanie J.
AU - LeMaistre, Charles F.
AU - Loberiza, Fausto
AU - Maziarz, Richard T.
AU - Rizzo, J. Douglas
AU - Joffe, Steven
AU - Parsons, Susan
AU - Majhail, Navneet S.
N1 - Funding Information:
Financial disclosure: This study had no specific funding or grant support. The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute, National Heart, Lung and Blood Institute, and National Institute of Allergy and Infectious Diseases ; Grant/Cooperative Agreement 5U01HL069294 from the National Cancer Institute and National Heart, Lung and Blood Institute ; Contract HHSH234200637015 C with the Health Resources and Services Administration; Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research ; and grants from Allos, Amgen, Angioblast, anonymous donation to the Medical College of Wisconsin, Ariad, Be the Match Foundation, Blue Cross and Blue Shield Association, Buchanan Family Foundation, CaridianBCT, Celgene, CellGenix, Children's Leukemia Research Association, Fresenius-Biotech North America, Gamida Cell Teva Joint Venture, Genentech, Genzyme, GlaxoSmithKline, HistoGenetics, Kiadis Pharma, Leukemia & Lymphoma Society, Medical College of Wisconsin, Merck & Co, Millennium: Takeda Oncology, Milliman USA, Miltenyi Biotec, National Marrow Donor Program, Optum Healthcare Solutions, Osiris Therapeutics, Otsuka America Pharmaceutical, RemedyMD, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals, Soligenix, StemCyte, Stemsoft Software, Swedish Orphan Biovitrum, Tarix Pharmaceuticals, Teva Neuroscience, Therakos, and Wellpoint. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, or any other agency of the US government.
PY - 2013/7
Y1 - 2013/7
N2 - Autologous hematopoietic cell transplantation (auto-HCT) is performed to treat relapsed and recurrent malignant disorders and as part of initial therapy for selected malignancies. This study evaluated changes in use, techniques, and survival in a population-based cohort of 68,404 patients who underwent first auto-HCT in a US or Canadian center between 1994 and 2005 and were reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The mean annual number of auto-HCTs performed was highest during 1996-1999 (6948), and decreased subsequently 2000-2003 (4783), owing mainly to fewer auto-HCTs done to treat breast cancer. However, the mean annual number of auto-HCTs increased from 5278 annually in 1994-1995 to 5459 annually in 2004-2005, reflecting increased use for multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma. Despite an increase in the median recipient age from 44 to 53years, there has been a significant improvement in overall survival (OS) from 1994 to 2005 in patients with chemotherapy-sensitive relapsed non-Hodgkin lymphoma (day+100 OS, from 85% to 96%; 1-year OS, from 68% to 80%; P<.001) and chemotherapy-sensitive multiple myeloma (day+100 OS, from 96% to 98%; 1-year OS, from 83% to 92%; P<.001). This improvement in OS was most pronounced in middle-aged (>40years) and older (>60years) individuals.
AB - Autologous hematopoietic cell transplantation (auto-HCT) is performed to treat relapsed and recurrent malignant disorders and as part of initial therapy for selected malignancies. This study evaluated changes in use, techniques, and survival in a population-based cohort of 68,404 patients who underwent first auto-HCT in a US or Canadian center between 1994 and 2005 and were reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The mean annual number of auto-HCTs performed was highest during 1996-1999 (6948), and decreased subsequently 2000-2003 (4783), owing mainly to fewer auto-HCTs done to treat breast cancer. However, the mean annual number of auto-HCTs increased from 5278 annually in 1994-1995 to 5459 annually in 2004-2005, reflecting increased use for multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma. Despite an increase in the median recipient age from 44 to 53years, there has been a significant improvement in overall survival (OS) from 1994 to 2005 in patients with chemotherapy-sensitive relapsed non-Hodgkin lymphoma (day+100 OS, from 85% to 96%; 1-year OS, from 68% to 80%; P<.001) and chemotherapy-sensitive multiple myeloma (day+100 OS, from 96% to 98%; 1-year OS, from 83% to 92%; P<.001). This improvement in OS was most pronounced in middle-aged (>40years) and older (>60years) individuals.
KW - Autologous transplantation
KW - Lymphoma
KW - Myeloma
KW - Survival
KW - Treatment-related mortality
UR - https://www.scopus.com/pages/publications/84879336748
U2 - 10.1016/j.bbmt.2013.04.027
DO - 10.1016/j.bbmt.2013.04.027
M3 - Article
C2 - 23660172
AN - SCOPUS:84879336748
SN - 1083-8791
VL - 19
SP - 1116
EP - 1123
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 7
ER -